Knowledge is Power

Journal of Sexual Medicine

Volumn 11, Issue 3, 2014, Pages 613-615

  Irwin, Goldstein ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ANDROGEN THERAPY; ANGIOCARDIOGRAPHY; EDITORIAL; FOLLOW UP; HEALTH CARE PERSONNEL; HEALTH HAZARD; HUMAN; HYPOGONADISM; KNOWLEDGE; LIBIDO; MOTIVATION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCIENTIFIC LITERATURE; SEXUAL HEALTH; STUDY DESIGN;

ANDROPAUSE; HUMANS; MALE; MYOCARDIAL INFARCTION; STROKE; TESTOSTERONE;

EID: 84895500913     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12466     Document Type: Editorial

References (27)

1. Vigen R, O'Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME, Rumsfeld JS, Ho PM. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310:1829-1836.
2. Beck M. Testosterone therapy tied to heart risks. Wall Street Journal, November 5, 2013. Available at: http://online.wsj.com/news/articles/SB10001424052702303661404579180294201174958 (accessed January 4, 2014).
3. Kim J. Testosterone therapy raises heart and death risks, study finds. Everyday Health, November 5, 2013. http://www.everydayhealth.com/low-testosterone/testosterone-therapy-raises-heart-and-death-risks-study-finds.aspx (accessed January 4, 2014).
4. Corona G, Rastrelli G, Maggi M. Diagnosis and treatment of late-onset hypogonadism: Systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab 2013;27:557-579.
5. Isidori AM, Buvat J, Corona G, Goldstein I, Jannini EA, Lenzi A, Porst H, Salonia A, Traish AM, Maggi M. A critical analysis of the role of testosterone in erectile function: From pathophysiology to treatment-a systematic review. Eur Urol 2014;65:99-112.
6. Francomano D, Ilacqua A, Bruzziches R, Lenzi A, Aversa A. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology 2014;83:167-174.
7. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013;169:725-733.
8. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters versus placebo in a population of men with type 2 diabetes. J Sex Med 2013;10:1612-1627.
9. Morales A. The long and tortuous history of the discovery of testosterone and its clinical application. J Sex Med 2013;10:1178-1183.
10. Corona G, Rastrelli G, Ricca V, Jannini EA, Vignozzi L, Monami M, Sforza A, Forti G, Mannucci E, Maggi M. Risk factors associated with primary and secondary reduced libido in male patients with sexual dysfunction. J Sex Med 2013;10:1074-1089.
11. Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: Systematic review and standard operating procedures for diagnosis and treatment. J Sex Med 2013;10:245-284.
12. Rubio-Aurioles E, Bivalacqua TJ. Standard operational procedures for low sexual desire in men. J Sex Med 2013;10:94-107.
13. Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M. IPASS: A study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1438 men. J Sex Med 2013;10:579-588.
14. Kaufman JM, Miller MG, Fitzpatrick S, McWhirter C, Brennan JJ. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: Results of a 182-day open-label extension of a 6-month double-blind study. J Sex Med 2012;9:1149-1161.
15. Corona G, Gacci M, Baldi E, Mancina R, Forti G, Maggi M. Androgen deprivation therapy in prostate cancer: Focusing on sexual side effects. J Sex Med 2012;9:887-902.
16. Di Sante S, Conners WP, Morgentaler A. Influence of baseline serum testosterone on changes in body composition in response to testosterone therapy. J Sex Med 2012;9:585-593.
17. Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Improved sexual function with testosterone replacement therapy in hypogonadal men: Real-world data from the Testim Registry in the United States (TRiUS). J Sex Med 2011;8:3204-3213.
18. Corona G, Rastrelli G, Forti G, Maggi M. Update in testosterone therapy for men. J Sex Med 2011;8:639-654.
19. Lin JW, Lee JK, Wu CK, Caffrey JL, Chang MH, Hwang JJ, Dowling N, Lin YS. Metabolic syndrome, testosterone, and cardiovascular mortality in men. J Sex Med 2011;8:2350-2360.
20. Carson CC III, Rosano G. Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: A review of trial data. J Sex Med 2012;9:54-67.
21. Corona G, Rastrelli G, Monami M, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Body mass index regulates hypogonadism-associated CV risk: Results from a cohort of subjects with erectile dysfunction. J Sex Med 2011;8:2098-2105.
22. Kaufman JM, Miller MG, Garwin JL, Fitzpatrick S, McWhirter C, Brennan JJ. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med 2011;8:2079-2089.
23. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M. Testosterone and metabolic syndrome: A meta-analysis study. J Sex Med 2011;8:272-283.
24. Permpongkosol S, Tantirangsee N, Ratana-olarn K. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: Effects on body composition, lipids, and psychosexual complaints. J Sex Med 2010;7:3765-3774.
25. Traish AM, Gooren LJ. Safety of physiological testosterone therapy in women: Lessons from female-to-male transsexuals (FMT) treated with pharmacological testosterone therapy. J Sex Med 2010;7:3758-3764.
26. Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, Cuzin B, Moncada I, Martin-Morales A, Yassin A, Meuleman E, Eardley I, Dean JD, Shabsigh R. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 2011;8:284-293.
27. Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, Spera G. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: Results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010;7:3495-3503.